Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa., PMID:40502542
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates., PMID:40500332
Nanobodies and their derivatives: pioneering the future of cancer immunotherapy., PMID:40474230
[Screening and characterization of camelid-derived nanobodies against hemoglobin]., PMID:40328713
[Construction and characterization of single-framework fully synthetic nanobody libraries]., PMID:40328712
Development of an Anti-Zearalenone Nanobody Phage Display Library and Preparation of Specific Nanobodies., PMID:40136411
A simple and effective method to remove pigments from heterologous secretory proteins expressed in Pichia pastoris., PMID:39883296
Peptidisc-Assisted Hydrophobic Clustering Toward the Production of Multimeric and Multispecific Nanobody Proteins., PMID:39810388
Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation., PMID:39637990
Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity., PMID:39603436
A Diketopinic Reagent for the Reversible Bioconjugation to Arginine Residues on Native Antibodies., PMID:39432883
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration., PMID:39397258
Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies., PMID:39036071
Oriented immobilization of nanobodies using SpyCatcher/SpyTag significantly enhances the capacity of affinity chromatography., PMID:38905946
Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy., PMID:38766114
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer., PMID:38755613
Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy., PMID:38737471
Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers., PMID:38580333
Sequence-based design and construction of synthetic nanobody library., PMID:38548653
Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species., PMID:38352869
An Albumin-Holliday Junction Biomolecular Modular Design for Programmable Multifunctionality and Prolonged Circulation., PMID:38231391
Crystal structure of human serum albumin in complex with megabody reveals unique human and murine cross-reactive binding site., PMID:38152025
Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration., PMID:38142486
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer., PMID:37932752
[Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 mg Syringes for S.C. Injection), the first Nanobody® compound in Japan]., PMID:37914330
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis., PMID:37909264
Alpha hemolysin of E. coli induces hemolysis of human erythrocytes independently of toxin interaction with membrane proteins., PMID:37820991
The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice., PMID:37730142
"Fluorescence-wavelength" label-free POCT tandem with "fluorescence-photothermal" nanobody-immunosensor for detecting BSA and β-lactoglobulin., PMID:37552900
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis., PMID:37431762
A few good reasons to use nanobodies for cancer treatment., PMID:37366246
Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor., PMID:37185766
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials., PMID:37055803
Isolation of atrazine nanobodies enhanced by depletion of anti-carrier protein phages and performance comparison between the nanobody and monoclonal antibody derived from the same immunogen., PMID:36737149
Discovery and characterization of hydroxylysine O-glycosylation in an engineered IL-2 fusion protein., PMID:36737029
Sensitive immunoassay of Legionella using multivalent conjugates of engineered VHHs., PMID:36525357
Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent., PMID:36368007
Statement of Retraction: Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer., PMID:36350994
A Nanobody-Based Immunoassay for Detection of Ustilaginoidins in Rice Samples., PMID:36287930
The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles., PMID:36177031
Antibody markup language (AbML) - a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)., PMID:35838549
Nanobody/NanoBiT system-mediated bioluminescence immunosensor for one-step homogeneous detection of trace ochratoxin A in food., PMID:35753304
An alpaca single-domain antibody (VHH) phage display library constructed by CDR shuffling provided high-affinity VHHs against desired protein antigens., PMID:35689594
CuS@BSA-NB2 Nanoparticles for HER2-Targeted Photothermal Therapy., PMID:35126119
The Therapeutic Effect of an Anti-TNF-α/HSA/IL-6R Triple-Specific Fusion Protein Under Experimental Septic Conditions., PMID:35059921
Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer., PMID:35019820
Maximizing response to intratumoral immunotherapy in mice by tuning local retention., PMID:35013154
Structural arrangement of the VH and VL domains in the COBRA™ T-cell engaging single-chain diabody., PMID:35005430
Evaluation and selection of potent fluorescent immunosensors by combining fluorescent peptide and nanobodies displayed on yeast surface., PMID:34799644
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade., PMID:34735918
For research use only. Not for human or drug use.
